Vemurafenib
Thyroid Gland Papillary Carcinoma
Explore 16 assets in Thyroid Gland Papillary Carcinoma →Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Cancer Research UK
Modality
Small molecule
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05768178CT.gov DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Thyroid Gland Papillary Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vemurafenib (this asset) | Cancer Research UK | P2/3 | CCC · 55 |
| Sorafenib | National Cancer Institute (NCI) | P2 | B |
| Trametinib | Cancer Research UK | P2/3 | B |
| Cobimetinib | Cancer Research UK | P2/3 | B |
| Dabrafenib | Cancer Research UK | P2/3 | B |
| Entrectinib | Hoffmann-La Roche | P2 | CCC |
| Alectinib | Hoffmann-La Roche | P2 | CCC |
| Nivolumab | Famewave Ltd. | P1/2 | CCC |
| Anti-Ceacam1 Monoclonal Antibody Cm-24 | Famewave Ltd. | P1/2 | CCC |
+22 more in the Thyroid Gland Papillary Carcinoma cohort
Other indications for Vemurafenib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P3 | BB · 66 |
| Metastatic Melanoma | — | P4 | B · 63 |
| Hematopoietic And Lymphoid System Neoplasm | — | P2/3 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vemurafenib in Thyroid Gland Papillary Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vemurafenib-thyroid-gland-papillary-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →